In patients with HF, SGLT2 inhibitors with high and low SGLT2/SGLT1 selectivity led to significantly reduced risks; nevertheless, the low selectivity inhibitors did not have significant risk reduction for patients without HF. This evidence concerns the gene SLC5A1 and hydrops fetalis.